A drug discovery company that uses single cell RNA sequencing technology to discover unique biological insights that were not identifiable otherwise. It combines proprietary scRNA methods and machine learning platform to identify underlining pathogenesis at a individual cell level.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $148M
Founded date: 2018
Investors 5
| Date | Name | Website |
| - | S32 | s32.com |
| - | Section 32 | section32.... |
| - | Fast Track... | us.fasttra... |
| - | Catalio Ca... | cataliocap... |
| - | GV | gv.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 25.03.2022 | - | $83M | - |
| 15.05.2018 | Series A | $65M | - |
Mentions in press and media 5
| Date | Title | Description | Source |
| 24.03.2022 | Celsius turns up the heat with lead drug selection, $83M fin... | The temperature is rising at Celsius Therapeutics as the precision-medicine-focused biotech picks a ... | fiercebiot... |
| 03.12.2020 | elluminate® Clinical Data Platform from eClinical Solutions ... | “The elluminate platform and Mapper application are designed to help life sciences companies like Ce... | prweb.com/... |
| 15.05.2018 | Celsius Therapeutics Launches with $65 Million in Series A F... | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Celsius Therapeutics, a company translating single-cell genomic i... | citybizlis... |
| 15.05.2018 | Term Sheet — Tuesday, May 15 | ALL BETS ARE ON Good morning, Term Sheet readers. Paid Content Securing the enterprise without bou... | fortune.co... |
| 15.05.2018 | Celsius Therapeutics Raises $65M in Series A Financing | Celsius Therapeutics, a Cambridge, MA-based company translating single-cell genomic insights into pr... | finsmes.co... |